NCT00398710View on ClinicalTrials.gov

A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

August 31, 2011

Study Completion Date

October 31, 2011

Conditions
Waldenström's Macroglobulinemia
Interventions
DRUG

Perifosine

150 mg daily (100 mg daily in case of dose reduction)

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

AEterna Zentaris
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

lead

AEterna Zentaris

INDUSTRY